These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27793950)

  • 21. Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.
    Hyman DM; Snyder AE; Carvajal RD; Gerecitano JF; Voss MH; Ho AL; Konner J; Winkelmann JL; Stasi MA; Monson KR; Iasonos A; Spriggs DR; Bialer P; Lacouture ME; Teitcher JB; Katabi N; Fury MG
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):747-55. PubMed ID: 25672916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.
    McKay RR; De Velasco G; Werner L; Bellmunt J; Harshman L; Sweeney C; Rosenberg JE; Hirsch M; Signoretti S; Van Allen EM; Walsh M; Vaishampayan U; McDermott DF; Choueiri TK
    Cancer; 2016 Aug; 122(15):2389-98. PubMed ID: 27198170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
    Papadopoulos KP; Tabernero J; Markman B; Patnaik A; Tolcher AW; Baselga J; Shi W; Egile C; Ruiz-Soto R; Laird AD; Miles D; Lorusso PM
    Clin Cancer Res; 2014 May; 20(9):2445-56. PubMed ID: 24583798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.
    McRee AJ; Sanoff HK; Carlson C; Ivanova A; O'Neil BH
    Invest New Drugs; 2015 Dec; 33(6):1225-31. PubMed ID: 26490655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Ma CX; Luo J; Naughton M; Ademuyiwa F; Suresh R; Griffith M; Griffith OL; Skidmore ZL; Spies NC; Ramu A; Trani L; Pluard T; Nagaraj G; Thomas S; Guo Z; Hoog J; Han J; Mardis E; Lockhart C; Ellis MJ
    Clin Cancer Res; 2016 Apr; 22(7):1583-91. PubMed ID: 26563128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Mayer IA; Abramson VG; Isakoff SJ; Forero A; Balko JM; Kuba MG; Sanders ME; Yap JT; Van den Abbeele AD; Li Y; Cantley LC; Winer E; Arteaga CL
    J Clin Oncol; 2014 Apr; 32(12):1202-9. PubMed ID: 24663045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma.
    Estévez LG; García E; Hidalgo M
    Clin Transl Oncol; 2016 Jun; 18(6):541-9. PubMed ID: 26510854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
    McPherson V; Reardon B; Bhayankara A; Scott SN; Boyd ME; Garcia-Grossman IR; Regazzi AM; McCoy AS; Kim PH; Al-Ahmadie H; Ostrovnaya I; Roth AJ; Farooki A; Berger MF; Rosenberg JE; Solit DB; Van Allen E; Milowsky MI; Bajorin DF; Iyer G
    Cancer; 2020 Oct; 126(20):4532-4544. PubMed ID: 32767682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.
    Owonikoko TK; Harvey RD; Carthon B; Chen Z; Lewis C; Collins H; Zhang C; Lawson DH; Alese OB; Bilen MA; Sica GL; Steuer CE; Shaib WL; Wu C; Harris WB; Akce M; Kudchagkar RR; El-Rayes BF; Lonial S; Ramalingam SS; Khuri FR
    Clin Cancer Res; 2020 Jun; 26(11):2497-2505. PubMed ID: 32005746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
    Wen PY; Rodon JA; Mason W; Beck JT; DeGroot J; Donnet V; Mills D; El-Hashimy M; Rosenthal M
    ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32661186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
    McGowan DR; Skwarski M; Bradley KM; Campo L; Fenwick JD; Gleeson FV; Green M; Horne A; Maughan TS; McCole MG; Mohammed S; Muschel RJ; Ng SM; Panakis N; Prevo R; Strauss VY; Stuart R; Tacconi EMC; Vallis KA; McKenna WG; Macpherson RE; Higgins GS
    Eur J Cancer; 2019 May; 113():87-95. PubMed ID: 30991262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.
    Netland IA; Førde HE; Sleire L; Leiss L; Rahman MA; Skeie BS; Miletic H; Enger PØ; Goplen D
    J Neurooncol; 2016 Aug; 129(1):57-66. PubMed ID: 27283525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of buparlisib in treating breast cancer.
    Robert M; Frenel JS; Bourbouloux E; Berton Rigaud D; Patsouris A; Augereau P; Gourmelon C; Campone M
    Expert Opin Pharmacother; 2017 Dec; 18(18):2007-2016. PubMed ID: 29169282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.
    Younes A; Salles G; Martinelli G; Bociek RG; Barrigon DC; Barca EG; Turgut M; Gerecitano J; Kong O; Pisal CB; Tavorath R; Kim WS
    Haematologica; 2017 Dec; 102(12):2104-2112. PubMed ID: 28971900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
    Heudel PE; Fabbro M; Roemer-Becuwe C; Kaminsky MC; Arnaud A; Joly F; Roche-Forestier S; Meunier J; Foa C; You B; Priou F; Tazi Y; Floquet A; Selle F; Berton-Rigaud D; Lesoin A; Kalbacher E; Lortholary A; Favier L; Treilleux I; Ray-Coquard I
    Br J Cancer; 2017 Jan; 116(3):303-309. PubMed ID: 28072765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
    Edelman G; Rodon J; Lager J; Castell C; Jiang J; Van Allen EM; Wagle N; Lindeman NI; Sholl LM; Shapiro GI
    Oncologist; 2018 Apr; 23(4):401-e38. PubMed ID: 29593099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.
    Molife LR; Dean EJ; Blanco-Codesido M; Krebs MG; Brunetto AT; Greystoke AP; Daniele G; Lee L; Kuznetsov G; Myint KT; Wood K; de Las Heras B; Ranson MR
    Clin Cancer Res; 2014 Dec; 20(24):6284-94. PubMed ID: 25278451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer.
    Lu YS; Lee KS; Chao TY; Tseng LM; Chitapanarux I; Chen SC; Liu CT; Sohn J; Kim JH; Chang YC; Yang Y; Shotelersuk K; Jung KH; Valenti R; Slader C; Gao M; Park YH
    Clin Cancer Res; 2021 Jan; 27(2):408-417. PubMed ID: 32718997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study.
    Rosenthal M; Clement PM; Campone M; Gil-Gil MJ; DeGroot J; Chinot O; Idbaih A; Gan H; Raizer J; Wen PY; Pineda E; Donnet V; Mills D; El-Hashimy M; Mason W
    ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32665311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
    Jänne PA; Cohen RB; Laird AD; Macé S; Engelman JA; Ruiz-Soto R; Rockich K; Xu J; Shapiro GI; Martinez P; Felip E
    J Thorac Oncol; 2014 Mar; 9(3):316-23. PubMed ID: 24496004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.